Overview

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

Status:
Unknown status
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a sirolimus-based maintenance immunosuppression regimen. The investigators hypothesize that the conversion from tacrolimus to sirolimus in African American renal recipients will stabilize or improve renal allograft function, and stabilize the histological progression of CAN. This conversion will have the potential to prolong long-term graft survival in African American renal transplant patients. GFR measurements, histological parameters on the allograft biopsy, as well as patient and graft survival, incidence of acute rejection, and specific side effects will be monitored and compared between the sirolimus conversion group and the patients who will be maintained on tacrolimus.
Phase:
Phase 4
Details
Lead Sponsor:
Temple University
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus
Tacrolimus